El Comité para la designación de medicamentos huérfanos (COMP) de la Agencia Europea del Medicamento (EMA) comunica a la compañía vasca Atlas Molecular Pharma S. L. su opinión favorable a la solicitud del fármaco L2.7.D7 para el tratamiento de la Porfiria Eritropoyética Congénita (PEC). La EMA otorga este reconocimiento tras un riguroso examen de los [...]

DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today a favourable report, as Orphan Medicinal Product, from the European Medicines Agency (EMA) for its candidate drug (L2.7.D7) for the treatment of Congenital Erythropoietic Porphyria. “The favorable [...]